Bharat Biotech starts trial of COVID-19 Vaccine at AIIMS Patna & PGIMS Rohtak. Furthermore, on Wednesday Bharat Biotech International Ltd. has started human trials. Hence for its vaccine ‘covaxin’ against COVID-19 virus. Which shall happen at AIIMS(All India Institute Of Medical Science), Patna. And PGIMS ( Pandit Bhagwat Dayal Sharma Post Graduate Institute Of Medical Science) , Rohtak, Haryana.
The trials begin for the first time on Wednesday in AIIMS Patna. Till now 9 people have been given small dosage of vaccine. After two weeks, if it will remain successful then it will be given to more people.
Health Minister of Haryana Anil Vij. has confirmed in his tweet that Biotech will start trial of covaxin in PGIMS from today.
Three subjects were enrolled today. All have tolerated the vaccine very well. There were no adverse efforts
Also, he tweeted.
Twelve Institutes are chosen for the phase 1 trial of covaxin. Which will take 1,125 subjects that will be tested. Moreover, the trial is developed by Bharat Biotech and Indian Council of Medical Research’s National Institute of Virology,Pune.
India’s First Indigenous Covid19 Vaccine Covaxin initiated phase-1 clinical trials across the country on 15th July 2020. This is a randomised, double-blind, placebo-controlled clinical trial in 375 volunteers in India.
Said spokesperson of Bharat Biotech,on Wednesday.
Covaxin was the first indigenous vaccine to receive the Drug Controller General of India V.G. Somani’s approval for human trial.
Phase 1 and Phase 2 trial will complete within 15 months.
